Saturday 17 October 2026
Export XBIT’s income statement to Excel — free account
XBiotech Inc.
XBIT Healthcare Biotechnology
XBiotech Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.0 million. In the quarter to June 2026, EPS fell 266.7% and free cash flow grew 25.3%, each against the same quarter a year earlier.
2.12
0.04
−1.85%
Follow XBIT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(16.23%) | (28.23%) | (25.93%) | (29.94%) | |
| (15.25%) | (26.08%) | (24.97%) | (28.90%) | ||
ROIC |
(109.96%) | (235.17%) | (154.70%) | (159.18%) | |
Return on Tangible Assets |
(17.27%) | (32.04%) | (29.35%) | (34.64%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.78) | (1.32) | (1.38) | (1.33) | |
Free Cash Flow |
(23.85) | (40.21) | (42.17) | (40.69) | |
Capital Expenditures |
(0.34) | (0.29) | — | — | |
| Other line items | |||||
Cash ROIC |
(7.58%) | (15.12%) | (16.84%) | (17.10%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.01 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.81 | 0.88 | 1.05 | 0.90 | |
Depreciation/Fixed assets |
0.07 | 0.07 | 0.07 | 0.06 | |
Capex/Depreciation |
(0.19) | (0.17) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.77) | (1.31) | (1.38) | (1.33) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates